Back In Stock Ergi-usu, Highly Selective Erg Inhibitor (tbi4290) ~ Limited Availability [lj46XyFG]

ERGi-USU: A Potent ERG Inhibitor

Introducing ERGi-USU, a highly selective ERG inhibitor designed to target specific cellular processes with precision. This innovative compound, also known as TBI4290, stands out for its ability to selectively inhibit the growth of ERG-positive cancer cells, including prostate and colon cancer cells, while minimizing its impact on normal cells. With its exceptional selectivity and minimal side effects, ERGi-USU offers a promising solution for cancer research and potential therapeutic applications.

Product Specifications and Properties

ERGi-USU is a pure powder with a molecular formula of C₁₃H₉N₃OS and a formula weight of 255.30. It boasts a high purity of >98% and is highly soluble in DMSO, up to at least 10 mg/ml. The compound is stable at -20°C and maintains its integrity for at least one year. Key specifications include a CAS number of 1147-56-4, and it is formulated for optimal performance in various biological assays.

Applications and Benefits

ERGi-USU is a powerful tool for researchers and clinicians in the field of oncology. It selectively inhibits the kinase RIOK2, disrupting ribosomal biogenesis and causing ribosomal stress, which is critical for the growth of cancer cells. This unique mechanism of action makes ERGi-USU an ideal candidate for the development of novel cancer therapies. Its minimal effect on ERG-negative cells and normal prostate or endothelial cells ensures a targeted approach with reduced risk of side effects. With ERGi-USU, researchers can explore the potential of ERG inhibition in treating various types of cancer, offering hope for patients and a significant advancement in cancer research.